Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Clicks: 450
ID: 115945
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 38 articles by views in clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Vedolizumab demonstrated significantly greater efficacy as induction and maintenance therapy for UC than placebo in patients naive to TNF antagonists and patients with TNF antagonist failure. There were numerically greater treatment differences at Week 6 among patients receiving vedolizumab who were …
Reference Key
bg2017clinicalefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Rubin DT;Danese S;Vermeire S;Abhyankar B;Sankoh S;James A;Smyth M;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2017
DOI
DOI not found
URL
https://www.pubmed.gov/27639327/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged randomized controlled trials as topic Antibodies Monoclonal Brian G Feagan Humanized / therapeutic use* Colitis Ulcerative / drug therapy* Gastrointestinal Agents / therapeutic use* placebos / administration & dosage pmid:27639327 doi:10.1016/j.cgh.2016.08.044 david t rubin michael smyth clinical trials phase iii as topic induction chemotherapy / methods maintenance chemotherapy / methods

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.